Drugs / CVD908ssb-TXSVN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03762291 | Aug 2021 → Mar 2022 | plasma cell myeloma | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVD908ssb-TXSVN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03762291 ↗ |
| Known as | TXSVN | “TXSVN, the modified strain of CVD908ssb has not been tested in humans to this date.” NCT03762291 ↗ |
| Action | Activate | “TXSVN may activate the immune system” NCT03762291 ↗ |
| Modality | Vaccine | “Multiple myeloma patients will receive a cancer vaccine, called TXSVN” NCT03762291 ↗ |